SFAM
Springhill Fund Asset Management Portfolio holdings
AUM
$20.9M
This Quarter Return
+8.77%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$20.9M
AUM Growth
+$20.9M
(-66%)
Cap. Flow
-$43.7M
Cap. Flow
% of AUM
-209.44%
Top 10 Holdings %
Top 10 Hldgs %
82.88%
Holding
30
New
13
Increased
2
Reduced
4
Closed
11
Top Buys
| 1 |
Summit Therapeutics
SMMT
|
$2.4M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$1.65M |
| 3 |
Neurocrine Biosciences
NBIX
|
$1.51M |
| 4 |
Janux Therapeutics
JANX
|
$1.32M |
| 5 |
Soleno Therapeutics
SLNO
|
$1.29M |
Top Sells
| 1 |
Legend Biotech
LEGN
|
$6.21M |
| 2 |
Cytokinetics
CYTK
|
$6.15M |
| 3 |
Akero Therapeutics
AKRO
|
$5.31M |
| 4 |
AstraZeneca
AZN
|
$5.01M |
| 5 |
Vera Therapeutics
VERA
|
$4.63M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
Verona Pharma
VRNA
$9.17B
| $4.03M | 19.32% |
63,499
-71,953
| -53% | -$4.57M |
|
|
2
Summit Therapeutics
SMMT
$17.7B
| $2.4M | 11.49% |
+124,307
| New | +$2.4M |
|
|
3
Janux Therapeutics
JANX
$1.36B
| $2.12M | 10.16% |
78,500
+48,900
| +165% | +$1.32M |
|
|
4
Regeneron Pharmaceuticals
REGN
$60.7B
| $1.65M | 7.9% |
+2,600
| New | +$1.65M |
|
|
5
Neurocrine Biosciences
NBIX
$14B
| $1.51M | 7.21% |
+13,612
| New | +$1.51M |
|
6
Insmed
INSM
$30.8B
| $1.46M | 7.02% |
19,192
-50,308
| -72% | -$3.84M |
|
|
7
Soleno Therapeutics
SLNO
$3.6B
| $1.42M | 6.8% |
19,858
+18,065
| +1,008% | +$1.29M |
|
8
Jazz Pharmaceuticals
JAZZ
$7.9B
| $1.22M | 5.86% |
+9,853
| New | +$1.22M |
|
|
9
Akero Therapeutics
AKRO
$3.66B
| $807K | 3.87% |
19,925
-131,275
| -87% | -$5.31M |
|
10
argenx
ARGX
$42.8B
| $678K | 3.25% |
+1,146
| New | +$678K |
|
11
Eli Lilly
LLY
$657B
| $674K | 3.23% |
+816
| New | +$674K |
|
12
Protagonist Therapeutics
PTGX
$3.67B
| $622K | 2.98% |
+12,859
| New | +$622K |
|
13
TG Therapeutics
TGTX
$4.68B
| $532K | 2.55% |
+13,500
| New | +$532K |
|
14
Tarsus Pharmaceuticals
TARS
$2.49B
| $363K | 1.74% |
+7,076
| New | +$363K |
|
15
Ascendis Pharma
ASND
$12.3B
| $339K | 1.62% |
+2,173
| New | +$339K |
|
16
Rhythm Pharmaceuticals
RYTM
$7.03B
| $332K | 1.59% |
+6,277
| New | +$332K |
|
17
BioNTech
BNTX
$24B
| $273K | 1.31% |
+3,000
| New | +$273K |
|
|
SWTX
18
DELISTED
SpringWorks Therapeutics
SWTX
| $260K | 1.25% |
+5,897
| New | +$260K |
|
19
Cogent Biosciences
COGT
$1.68B
| $177K | 0.85% |
29,491
-519,063
| -95% | -$3.11M |
|
|
ABVX
20
Abivax
ABVX
$6.16B
| – | – |
-207,600
| Closed | -$1.52M |
|
|
21
AstraZeneca
AZN
$247B
| – | – |
-76,500
| Closed | -$5.01M |
|
|
BCYC
22
Bicycle Therapeutics
BCYC
$505M
| – | – |
-116,400
| Closed | -$1.63M |
|
23
Cullinan Oncology
CGEM
$449M
| – | – |
-276,400
| Closed | -$3.37M |
|
|
24
Cytokinetics
CYTK
$5.94B
| – | – |
-130,735
| Closed | -$6.15M |
|
|
DRUG
25
Bright Minds Biosciences
DRUG
$276M
| – | – |
-60,648
| Closed | -$2.18M |
|